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Coronavirus replication is facilitated by a number of highly conserved viral proteins. The viruses also encode
accessory genes, which are virus group specific and believed to play roles in virus replication and pathogenesis
in vivo. Of the eight putative accessory proteins encoded by the severe acute respiratory distress syndrome
associated coronavirus (SARS-CoV), only two—open reading frame 3a (ORF3a) and ORF7a—have been
identified in virus-infected cells to date. The ORF7b protein is a putative viral accessory protein encoded on
subgenomic (sg) RNA 7. The ORF7b initiation codon overlaps the ORF7a stop codon in a 1 shifted ORF. We
demonstrate that the ORF7b protein is expressed in virus-infected cell lysates and from a cDNA encoding the
gene 7 coding region, indicating that the sgRNA7 is bicistronic. The translation of ORF7b appears to be
mediated by ribosome leaky scanning, and the protein has biochemical properties consistent with that of an
integral membrane protein. ORF7b localizes to the Golgi compartment and is incorporated into SARS-CoV
particles. We therefore conclude that the ORF7b protein is not only an accessory protein but a structural
component of the SARS-CoV virion.
In 2002, a severe acute respiratory distress syndrome
(SARS) of unknown etiology originated in China and subse-
quently spread to 32 countries on five continents, resulting in
more than 8,000 suspected cases and a mortality rate of almost
11% (5). By March of 2003, the causative agent was identified
as a novel coronavirus, SARS-CoV (13, 30, 51, 83), and the
viral genome was sequenced and annotated (40, 62, 80a).
The SARS-CoV genome consists of genes characteristic
of coronaviruses, including a bicistronic replicase (1a and
1b), nucleocapsid (N), envelope (E), membrane (M), and
spike (S) (Fig. 1). These genes are essential for virus repli-
cation (4a). Coronaviruses and other members of the
Nidovirales often contain additional genes that have no ho-
mologues in other, closely related viruses. These genes often
are not required for viral replication in vitro but do contrib-
ute to viral fitness and pathogenesis in vivo (reviewed in
reference 4a), hence their designation as accessory or
group-specific genes. The SARS-CoV genome contains
eight group-specific open reading frames (ORFs) (40, 62,
80a) that are conserved between human and animal isolates
of SARS-CoV and in closely related coronaviruses (8, 32,
35). To date, the only group-specific ORFs documented to
be expressed in SARS-CoV-infected cells are ORF3a and
ORF7a (7, 14a, 33, 47, 79, 87a). ORF3a is incorporated into
SARS-CoV particles and virus-like particles (25, 68). The
ORF7a protein is expressed in SARS-CoV-infected cells (6,
7, 47), localizes to the Golgi compartment (28, 47) and,
when overexpressed, induces apoptosis and inhibits host cell
protein synthesis (7, 28, 77, 87a). The X-ray crystal and
nuclear magnetic resonance structures of ORF7a have been
determined (17, 47), and the protein has been found in
SARS-CoV particles and virus-like particles (21).
The SARS-CoV accessory genes are dispensable for virus
replication in transformed cell lines, primary cell cultures, and
the murine model of virus infection (69, 85a, 85b). However,
the murine model for SARS-CoV infection does not show
significant morbidity or mortality after infection. Therefore, it
may not be an appropriate model for studying SARS-CoV
pathogenesis and accessory gene function (75).
The SARS-CoV ORF7b protein is predicted to be a 44-
amino-acid, highly hydrophobic protein with no identified se-
quence homology to other viral or cellular proteins. Given the
highly hydrophobic nature of ORF7b, it has been hypothesized
that ORF7b is a transmembrane protein and possibly a viral
structural protein (1). Although the expression of ORF7b in
virus-infected cells has not been documented to date, ORF7b-
specific antibodies have been detected in SARS patient con-
valescent-phase serum (16b). Whereas the ORF7b coding re-
gion is highly conserved among sequenced SARS-CoV
isolates, serial passage of SARS-CoV in Vero cells resulted
in a 29-nucleotide deletion in ORF7b, demonstrating that
the putative ORF7b protein is not essential for viral repli-
cation in vitro (80a).
We provide the first biochemical evidence for ORF7b ex-
pression in SARS-CoV-infected cells. We demonstrate that
ORF7b localizes to the Golgi complex, is an integral mem-
brane protein, is translated from the gene 7 mRNA via ribo-
somal leaky scanning, is associated with intracellular virus par-
ticles, and is present in purified virus particles.
* Corresponding author. Mailing address: Department of Molecular
Microbiology, Washington University School of Medicine, Campus
Box 8230, 660 S. Euclid Ave., St. Louis, MO 63110-1093. Phone: (314)
747-2132. Fax: (314) 362-7325. E-mail: pekosz@borcim.wustl.edu.
 Published ahead of print on 1 November 2006.
718
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Cells. Vero (ATCC CRL-1586) and 293T (76) cells were cultured in Dulbecco
modified Eagle medium containing 10% fetal bovine serum (Atlanta Biologi-
cals), 1 mM glutamine, 1 mM sodium pyruvate (Invitrogen), 100 U of penicillin
(Invitrogen)/ml, and 100 g of streptomycin (Invitrogen)/ml. Cells were incu-
bated in a 5% CO2 humidified incubator at 37°C.
Viruses. All infections were performed in a biosafety level 3 laboratory using
institution-approved procedures. SARS-CoV stocks (Urbani strain, courtesy of the
Centers for Disease Control and Prevention) were generated by infecting Vero cells
with SARS-CoV at a multiplicity of infection (MOI) of 0.01, followed by incubation
at 37°C (47). Infected-cell supernatants were harvested 48 h postinfection, clarified
by centrifugation at 1,000  g, divided into aliquots, and stored at 70°C.
FIG. 1. SARS-CoV genomic organization and expression of the accessory protein ORF7b. (A) Genomic organization and sgRNAs of
SARS-CoV. The 29-kb genome is transcribed into nine 3-coterminal subgenomic RNAs in virus-infected cells. The sgRNAs encode replicase
proteins (1a and 1b, white boxes) structural proteins (S, E, M, and N, black boxes), as well as eight proteins of unknown function (ORF3a, ORF3b,
ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b, gray boxes). The ORF7a and ORF7b proteins are encoded by sgRNA 7, with the ORF7a
stop codon and the ORF7b initiation codon overlapping. The nucleotide and amino acid sequences for the ORF7a/ORF7b overlap region are
shown. (B) Amino acid sequence of the ORF7b protein. The ORF7b protein is 44 amino acids in length with a single transmembrane domain
(underlined) predicted by TMPred. (C) Vero cells were either mock infected or infected with SARS-CoV at an MOI of 5.0 for 18 h. The expression
of ORF7b, N, and -actin was determined by Western blotting. The band at 75 kDa is an unidentified cellular protein detected by the ORF7b
sera. (D) Vero cells were either mock infected or infected with SARS-CoV at an MOI of 5.0 for 18 h. The cells were then processed for flow
cytometry using antibodies specific for the ORF7a (horizontal axis) or ORF7b (vertical axis) proteins.
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Infectious virus titers were determined by plaque assay or 50% tissue culture
infectious dose (TCID50). PFU per ml were determined by serially diluting
SARS-CoV in 10-fold increments and then incubating 250 l of each dilution
with Vero cells in six-well plates for 1 h at room temperature in quadruplicate.
The inoculum was replaced with warm Dulbecco modified Eagle medium con-
taining 10% fetal bovine serum, 1 mM glutamine, 1 mM sodium pyruvate, 100 U
of penicillin/ml, 100 g of streptomycin/ml, and 1% Ultrapure agarose (Invitro-
gen). When virus plaques were visible (usually after 4 days at 37°C), 1 ml of 1%
formaldehyde in phosphate-buffered saline (PBS) was added to each well. One
hour later, the formaldehyde and agarose was removed, and virus plaques were
visualized by staining with naphthol blue-black. The TCID50 per ml was deter-
mined by serially diluting SARS-CoV in 10-fold increments and then adding 100
l of each dilution to Vero cells in a 96-well plate in sextuplicate. The cells were
incubated at 37°C for 4 days, visualized by staining with naphthol blue-black, and
scored visually for cytopathic effect. A Reed and Muench calculation was used to
determine TCID50 per ml (59).
To generate infected cells and infected cell lysates, Vero cells were incubated
in 250 l of medium containing SARS-CoV at various MOIs for 1 h at 37°C. The
medium was aspirated, fresh medium was added, and cells were incubated for
designated time periods at 37°C. Cells were lysed in 1% sodium dodecyl sulfate
(SDS) or fixed with 2% paraformaldehyde in PBS.
For virion purification, Vero cells were infected at an MOI of 0.1 and incu-
bated at 37°C for 48 h. The infected cells were lysed with 1% SDS. The infected-
cell supernatant was collected and centrifuged at 1,000  g for 10 min to remove
cells and cellular debris.
Ultracentrifugation. The virus-containing supernatant was collected, and virus
was inactivated by either (i) the addition of an equal volume of 4% paraform-
aldehyde and incubation at 4°C overnight or (ii) the addition of 0.05% -pro-
piolactone and incubation at 4°C overnight, followed by incubation at 37°C for
2 h to allow -propiolactone breakdown into nontoxic by-products (58, 71). The
inactivated virions were pelleted by centrifugation over a 20% sucrose cushion at
100,000 g for 1 h in an SW41 ultracentrifuge rotor. The pellet was resuspended
in 2 Laemmli SDS loading buffer for Western blotting, in PBS for analysis by
electron microscopy, or in NTE (100 mM Nacl, 10 mM Tris-HCl [pH 7.4], and
1 mM EDTA) for analysis by sucrose gradient ultracentrifugation. For sucrose
gradient ultracentrifugation, the resuspended virus was loaded onto a continuous
20 to 60% sucrose gradient in NTE and centrifuged at 100,000  g for 18 h in an
SW41 ultracentrifuge rotor (50, 88). Then, 1-ml fractions were collected from the
top of the centrifuge tube, and the virus was concentrated from each fraction by
addition of 11 ml of NTE, followed by centrifugation at 100,000  g for 2 h in an
SW41 rotor. The resulting pellets were resuspended in 100 l of 2 Laemmli
SDS sample buffer and loaded onto SDS–15% polyacrylamide gel electrophore-
sis (PAGE) gels.
Plasmids. SARS-CoV viral RNA (Urbani strain, GenBank accession no.
AY278741) was purified from infected cell supernatant using the QIAamp viral
RNA purification kit (QIAGEN) according to the manufacturer’s protocol. A
cDNA encoding the entire gene 7 (7ab) was amplified by reverse transcription
(RT)-PCR from the purified viral RNA using Superscript One-Step RT-PCR
mix (Invitrogen) and oligonucleotide primers (primer sequences available upon
request). Based on the Urbani strain sequence with the ORF7a initiation codon
at positions 27273 to 27275, nucleotides 27268 through 27772 were isolated by
PCR, cloned into the eukaryotic expression plasmid pCAGGS (48), and se-
quenced. This construct was subsequently used as a template for cloning all
remaining ORF7ab and ORF7b constructs. The ORF7b coding region spanning
nucleotides 27638 to 27772 (Urbani sequence) was isolated by PCR and cloned
into the pCAGGS plasmid. PCR was then used to add the myc epitope sequence
to the C terminus of the ORF7b cDNA (ORF7b-myc). The cDNA constructs
encoding ORF7a and ORF7a fused to green fluorescent protein (ORF7a-GFP)
were described previously (47).
For bacterial expression, full-length ORF7b was isolated by PCR and cloned
into the pET28a bacterial expression vector (Invitrogen), resulting in an ORF7b
construct containing an N-terminal His6 epitope tag (His6-ORF7b).
The ORF7ab constructs detailed in Fig. 2A were generated by using overlap
PCR and encode the following mutations: 7ab 7a Kozak, nucleotides 27268 to
27272 (CGAAC) to GCCACC and nucleotides 27276 to 27277 (AA) to GC; 7ab
ATG, nucleotide 27443 (T) to A; 7ab 7a Stop, nucleotide 27276 (A) to T and
nucleotides 27291 to 27292 (CT) to TA;7ab 7a Stop KO, nucleotides 27641 to
27642 (AA) to GC; 7ab 7a Start KO, nucleotide 27275 (G) to C; and 7ab 7b Start
KO, nucleotide 27640 (G) to A.
A plasmid (pEGFP-C1 vector; Clontech) containing the cDNA for GFP fused
to the N terminus of Rab11 (GFP-Rab11) was provided by Phil Stahl, Washing-
ton University, St. Louis, MO. The expression vector for the influenza A virus
M2 cDNA (pCAGGS M2) was described previously (42, 43). PCR was used to
add the myc epitope sequence to the C terminus of the M2 ORF, generating the
pCAGGS M2-Myc plasmid. The S15-GFP cDNA contains the GFP ORF fused
to the first 15 amino acids of Src protein tyrosine kinase and has been described
previously (60a).
Antiserum to ORF7b. The pET28a ORF7b plasmid was transformed into
BL21 cells and grown in 1 liter of Luria broth at 37°C to an optical density of 0.7
at 600 nm. The cells were induced with 1 mM IPTG (isopropyl--D-thiogalacto-
pyranoside) for 4 h at 25°C, collected by centrifugation at 7,000 g, resuspended
in denaturing lysis buffer (6 M guanidine HCl, 20 mM NaPO4, 500 mM NaCl [pH
7.8]), and sonicated on ice (550 Sonic Dismembranator). The His6-ORF7b pro-
tein was then purified using a ProBond column per manufacturer recommenda-
tions (Invitrogen). Purified His6-ORF7b protein was used to immunize New
Zealand White rabbits using Ribi adjuvant (Covance, Pennsylvania).
Transient transfection of mammalian cells. 293T cells (1.5  105) were plated
into a 9.5-cm2 tissue culture dish (Corning) and allowed to attach for 24 h at
37°C. Approximately 1 g of DNA was mixed with 2 l of LT-1 transfection
reagent (Mirus) and incubated with the cells for 18 h at 37°C. For confocal
microscopy, 7.5  104 Vero cells were plated into a 9.5-cm2 dish (Corning)
containing glass coverslips and allowed to attach for 24 h at 37°C. Approximately
0.5 g of DNA was mixed with 2 l of LT-1 transfection reagent (Mirus) and
incubated with the cells for 18 h at 37°C.
FACS. Fluorescence-activated cell sorting (FACS) was performed as described
previously (47). Cells were incubated with the anti-ORF7a murine monoclonal
antibody (MAb) 2E11 (1:1,000 dilution) or anti-ORF7b rabbit serum (1:1,000
dilution), followed by goat anti-mouse immunoglobulin G (IgG; 1:500 dilution,
Alexa Fluor 488 labeled; Molecular Probes) or goat anti-rabbit IgG (1:500
dilution, AlexaFluor 647 labeled; Molecular Probes) secondary antibody. All
antibody dilutions were made in blocking buffer (PBS with 3% normal goat
serum [NGS], 0.5% bovine serum albumin, and 0.1% saponin), and wash buffer
consisted of PBS with 0.1% saponin. The cells were analyzed with a FACSCalibur
dual-laser flow cytometer (Becton Dickinson), and data were collected by using
CellQuest software.
Indirect immunofluorescence analysis and confocal microscopy. For indirect
immunofluorescence analysis, cells were washed three times with PBS, fixed with
2% paraformaldehyde in PBS for 10 min, washed three times with PBS, and then
blocked in PBS containing 3% NGS (Sigma) and 0.5% bovine serum albumin for
10 min. The cells were then incubated with antibody diluted in blocking buffer.
Primary antibodies were used as follows: rabbit anti-ORF7b polyclonal serum
(1:1,000 dilution), anti-ORF7a mouse MAb 2E11 (1:1,000 dilution) (47), anti-
influenza M2 mouse MAb 14C2 (1:1,000 dilution) (42, 43), anti-GM130 mouse
MAb (1:100 dilution; BD Biosciences), anti-Golgin-97 mouse MAb (1:100 dilu-
tion; Molecular Probes), goat anti-calnexin IgG (1:100 dilution; Santa Cruz
Biotechnology), rabbit anti-ERGIC53 IgG (1:100 dilution, Sigma), anti-CD63
mouse MAb (1:1,000 dilution, clone H5C6; BD Biosciences Pharmingen), anti-
c-Myc mouse MAb (1:50 dilution, supernatant from hybridoma 9E10, ATCC
CRL-1729). Cells were then washed three times with PBS and incubated with
secondary antibody (goat anti-mouse IgG Alexa Fluor 488, goat anti-mouse IgG
Alexa Fluor 594, goat anti-rabbit IgG Alexa Fluor 488, or goat anti-rabbit IgG
Alexa Fluor 594; Molecular Probes) as appropriate (1:500 dilution). Nuclei were
counterstained concurrently with TO-PRO-3 iodide (Molecular Probes). Where
appropriate, cells were permeabilized by including 0.1% saponin in all antibody
dilutions and wash buffers. For plasma membrane permeabilization, Vero cells
were placed on ice at 18 h posttransfection and washed with KHM buffer (110
mM potassium acetate, 20 mM HEPES [pH 7.2], 2 mM magnesium acetate).
Cells were then permeabilized in KHM buffer containing 25 g of digitonin/ml
on ice for 5 min, washed three times with KHM buffer, and fixed with 2%
paraformaldehyde in PBS on ice for 10 min (10, 54). Coverslips were mounted
onto microscope slides by using Prolong Antifade Gold (Molecular Probes) and
visualized on a Zeiss LSM 510 confocal microscope. Colocalization was quanti-
fied by using Volocity image analysis software (Improvision).
SDS-PAGE and Western blotting. Transfected or infected cells were lysed in
1% SDS in water and mixed at a 1:1 ratio with Laemmli 2 SDS-PAGE sample
buffer with or without 200 mM dithiothreitol (DTT) and boiled for 5 min (50).
Purified virions were resuspended in 2 SDS-PAGE sample buffer. Samples
were loaded onto either 15% polyacrylamide gels or 17.5% polyacrylamide gels
with 4 M urea (Mini Trans-Blot; Bio-Rad).
For Western blotting, separated polypeptides were transferred onto polyvi-
nylidene difluoride membranes (Millipore) and blocked in PBS containing 0.3%
Tween 20 and 5% nonfat dry milk (block buffer). Membranes were incubated
with the following antibodies diluted in block buffer: rabbit anti-ORF7b serum
(1:1,000 dilution), rabbit anti-SARS-CoV nsp8 protein (1:2,000 dilution) (56),
anti-SARS-CoV N mouse MAb 87-A1 (1:1,000 dilution) (64), anti-SARS mouse
hyperimmune serum (1:1,000 dilution, kindly provided by CDC), anti--actin
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mouse MAb (1:7,500 dilution; Abcam), anti-influenza A M2 mouse MAb 14C2
(1:2,000 dilution), anti-West Nile virus (WNV) NS1 mouse MAb 3NS1 (1:1,000)
(9), or rabbit anti-GFP sera (1:2,500 dilution; Molecular Probes). Primary anti-
bodies were detected by using species-specific IgG secondary antibodies coupled
to horseradish peroxidase (Jackson Laboratories). The blots were soaked in
chemiluminescent reagent (ECL Plus Pico; Amersham Biosciences) and imaged
by using either chemiluminescence and exposure to X-ray film (Molecular Tech-
nologies) or chemifluorescence followed by phosphorimager analysis (FujiFilm
FLA-5000) to quantify the signal intensity.
Membrane association assay. 293T cells were transfected with plasmids en-
coding the cDNAs for influenza A virus M2, SARS-CoV GFP-N, GFP-Rab11, or
ORF7b. At 18 h posttransfection, cells were collected and centrifuged at 300  g.
The cell pellet was resuspended in hypotonic lysis buffer (10 mM Tris [pH 7.4],
10 mM KCl, 5 mM MgCl2, and a protease inhibitor cocktail) and incubated on
ice for 30 min. Cells were lysed with 20 strokes of a Dounce homogenizer. Nuclei
and intact cells were removed by centrifugation at 1,000  g for 10 min. Post-
nuclear supernatants were separated into four aliquots and centrifuged at
100,000  g for 2 h in a TLA 45 rotor (Beckman) at 4°C to separate membrane
and cytosolic fractions. The high-speed supernatant was collected, and the high-
speed pellet (HSP) containing the membrane fraction was resuspended in 250 l
of 1 NTE buffer (0.5 M NaCl, 10 mM Tris-HCl [pH 7.4], 5 mM EDTA). To
dissociate peripheral membrane proteins (52), HSP suspensions were mixed with
an equal volume of 8 M urea, 4 M KCl, or 100 mM carbonate buffer (pH 11.3)
and incubated on ice for 30 min. HSP suspensions were then centrifuged at
100,000  g for 2 h in a TLA 45 rotor at 4°C, the supernatant was collected, and
the pellet resuspended in 2 Laemmli SDS-PAGE loading buffer.
Electron microscopy. At 12 h postinfection SARS-CoV-infected cells were
fixed with 4% paraformaldehyde–0.1% glutaraldehyde on ice for 60 min as
previously described (38, 38a) and processed further for cryofixation and cryo-
sectioning. Ultrathin cryosections were excised from the fixed material and
immunolabeled with anti-ORF7b rabbit serum and/or an anti-N MAb. Antibody
staining was visualized with protein A conjugated to 10- or 5-nm gold particles
(Utrecht University, Utrecht, The Netherlands), as described previously (38,
38a). The immunolabeled sections were viewed on a JOEL 1010 transmission
electron microscope and images were captured on a MegaView III side-mounted
charge-coupled device camera (Soft Imaging Systems) and processed for publi-
cation in Adobe Photoshop.
RESULTS
Expression of ORF7b in SARS-CoV-infected cells. The
SARS-CoV genome encodes nine RNA species that serve as
mRNAs for all of the proteins encoded by the virus (Fig. 1A).
FIG. 2. The ORF7b protein is translated via ribosome leaky scanning. (A). Schematic diagram of the cDNA constructs used to assess the
translation of ORF7b. Gene 7 constructs included wild-type sequence (7ab), an optimal translation initiation consensus sequence at the ORF7a
initiation codon (7ab 7a Kozak), a point mutation within the ORF7a coding region creating an out-of-frame ATG that does not alter the ORF7a
amino acid sequence (7ab ATG), two point mutations within the ORF7a ORF resulting in two in-frame stop codons (7ab 7a Stop), a point
mutation eliminating the ORF7a stop codon (7ab 7a Stop KO), a point mutation eliminating the ORF7a initiation codon (7ab 7a Start KO), and
a point mutation eliminating the ORF7b initiation codon (7ab 7b Start KO). All ATG sequences are boxed, and stop codons are italicized.
(B) 293T cells were transfected with plasmids encoding the indicated cDNAs and analyzed for ORF7a (horizontal axis) and ORF7b (vertical axis)
expression by flow cytometry at 18 h posttransfection. (C) 293T cells were transfected with plasmids encoding the indicated cDNAs, lysed 18 h
posttransfection, and analyzed for ORF7b and -actin expression by Western blotting. (D) The ORF7b protein band intensities from panel C were
quantified and normalized to -actin expression by using phosphorimager analysis. The quantified data are from five independent experiments.
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The 5 end of each subgenomic RNA (sgRNA) is defined by
the presence of a transcription regulatory sequence and the
existence of the nine sgRNAs has been confirmed experimen-
tally (70, 80a, 85b). Several of the sgRNAs are predicted to
encode more than one protein (Fig. 1A). In some cases
(sgRNAs 3 and 9) the two ORFs overlap significantly, while in
others (sgRNAs 1, 7, and 8) the overlap is minimal. In all cases,
the second ORF encoded by the sgRNA is in an unfavorable
location for translation since it is located downstream of at
least one initiation codon.
Although the expression of several SARS-CoV group-spe-
cific ORFs has been confirmed in tissue culture or in SARS-
CoV-infected tissue samples (6, 7, 14a, 47, 78, 86), there have
been no reports regarding the expression of the ORF7b pro-
tein. The ORF7b protein is encoded by an ORF beginning 365
nucleotides from the transcription regulatory sequence of
sgRNA7. The putative start codon for ORF7b overlaps but is
out of frame with the stop codon for ORF7a (Fig. 1A). SARS-
CoV ORF7b is predicted to be a 44-amino-acid protein con-
taining a hydrophobic central region that could span the mem-
brane bilayer (Fig. 1B). Of the 130 SARS-CoV isolates that
have been completely sequenced to date, 118 isolates have
identical ORF7b amino acid sequences, 1 isolate has a single
amino acid change in ORF7b, and 11 isolates have insertions
or deletions that severely disrupt the ORF7b coding region
(data not shown). The ORF7b proteins encoded by the eight
bat coronavirus isolates sequenced to date contain only two to
four amino acid changes from the sequence present in the
majority of SARS-CoV isolates, suggesting a selective pressure
to maintain the ORF7b ORF (32, 35, 55).
Sera from rabbits immunized with a bacterially expressed
His6-ORF7b fusion protein recognized a protein band that
migrated slightly faster than the 10-kDa molecular mass
marker and was found in SARS-CoV-infected Vero cell lysates
but not in mock-infected cell lysates (Fig. 1C). The expression
of ORF7b was also confirmed by flow cytometry. Antibodies
specific for the ORF7a (47) or ORF7b proteins reacted with
SARS-CoV-infected cells but not with mock-infected cells
(Fig. 1D). Most of the SARS-CoV-infected cells reacted with
both ORF7a- and ORF7b-specific antibodies, indicating that
both proteins were expressed in the same cells. These data
indicate that the ORF7b protein is expressed in SARS-CoV-
infected cells.
Expression of ORF7b from cDNA. To confirm that the
ORF7b protein can be expressed from an mRNA correspond-
ing to the SARS-CoV sgRNA7, the sequences encoding both
ORF7a and ORF7b (7ab) were amplified by reverse transcrip-
tase PCR and cloned into the eukaryotic expression vector
pCAGGS. Plasmids containing the coding regions for ORF7a
or ORF7b were also constructed (Fig. 2A). The plasmids were
transfected into 293T cells, and the expression of ORF7a or
ORF7b was quantified by using flow cytometry. Antibodies
specific for the ORF7a protein reacted with cells transfected
with the cDNA encoding ORF7a or ORF7ab (Fig. 2B). Anti-
bodies directed against the ORF7b protein recognized cells
transfected with cDNAs encoding ORF7b or the ORF7ab,
indicating the ORF7b protein could in fact be translated from
an mRNA containing the entire gene 7 coding region, despite
its position downstream of the ORF7a ORF (Fig. 2B). Neither
antibody recognized mock-transfected cells.
The entire gene 7 coding region contains only three ATG
codons. The first is predicted to initiate translation of ORF7a,
and the second is predicted to serve as the initiation codon for
the ORF7b protein (Fig. 2A). A third ATG resides immedi-
ately 3 to the predicted ORF7b initiation codon, but transla-
tion initiation at this site would result in a peptide of only four
amino acid residues. To confirm that the predicted ORF7a and
ORF7b initiation codons were functional, the codons were
mutated in the 7ab cDNA (7ab 7a Start KO and 7ab 7b Start
KO, Fig. 2A), and protein expression after transfection into
293T cells was quantified by flow cytometry (Fig. 2B). Mutating
the upstream ATG to ATC resulted in a loss of ORF7a ex-
pression, whereas mutating the downstream ATG to ATA
resulted in a loss of ORF7b expression, confirming that these
ATG codons were in fact the initiation codons for ORF7a and
ORF7b (Fig. 1B).
Leaky scanning translation of ORF7b. The downstream
ORF in multicistronic mRNAs can be translated via a variety
of mechanisms (reviewed in reference 29). Since the upstream
ATG in the sgRNA 7 cDNA is in a poor translational or Kozak
context (29), it seemed reasonable to surmise that the trans-
lation of ORF7b from sgRNA 7 occurred via leaky scanning.
To test this hypothesis, the plasmid containing the entire gene
7 coding region was mutated to (i) place the ORF7a ATG in an
ideal Kozak context (7ab 7a Kozak), (ii) introduce an addi-
tional ATG into the ORF7a ORF (7ab ATG), (iii) insert a stop
codon into the ORF7a ORF (7ab 7a Stop), (iv) eliminate the
ORF7a stop codon (7ab 7a Stop KO), and (v) eliminate
the ORF7a initiation codon (7ab 7a Start KO) (Fig. 2A). The
plasmids were transfected into 293T cells, and the cells were
lysed 18 h posttransfection. The expression of ORF7b and
-actin was detected by Western blotting (Fig. 2C) and quan-
tified by phosphorimager analysis (Fig. 2D). The ORF7b pro-
tein was expressed at a 2-fold higher amount from a plasmid
encoding only the ORF7b cDNA compared to that from a
plasmid expressing the full 7ab coding region, indicating that
the ORF7b expression from the 7ab cDNA was inefficient. If
ORF7b translation occurred by ribosome leaky scanning, then
changing the context of the ORF7a initiation codon to an
optimal Kozak sequence (Fig. 2A) should result in fewer ribo-
somes scanning past the ORF7a initiation codon, thereby re-
ducing the amount of ORF7b expression. The expression of
ORF7b from the 7ab 7a Kozak construct was significantly
reduced (Fig. 2C), suggesting that leaky scanning translation
could be responsible for the expression of ORF7b. The pres-
ence of additional ATG codons upstream of the ORF7b initi-
ation codon, particularly ones that are in an optimized Kozak
context, should result in reduced ORF7b expression since ri-
bosomes that have scanned past the ORF7a initiation codon
would encounter and engage at these initiation codons and not
scan further down the mRNA (29). When an out-of-frame
ATG codon in a near-optimal Kozak context was introduced
into the ORF7a coding region, the expression of ORF7b was
reduced (Fig. 2C, 7ab ATG), further supporting leaky scanning
as the mechanism of ORF7b translation. The introduction of
two premature stop codons into the ORF7a coding region (Fig.
2C, 7ab 7a Stop) or the elimination of the ORF7a stop codon
(Fig. 2C, 7ab 7a Stop KO) had little effect on the expression of
ORF7b. Eliminating the ORF7a start codon resulted in an ca.
50% increase in ORF7b expression (Fig. 2C, 7ab 7a Start KO).
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Eliminating the ORF7b initiation codon resulted in a complete
loss of ORF7b expression (Fig. 2C, 7ab 7b Start KO). Taken
together, the data in Fig. 2 indicate that the gene 7 mRNA is
bicistronic and the translation of ORF7b from this mRNA
occurs via ribosome leaky scanning.
ORF7b is an integral membrane protein. The ORF7b amino
acids 9 to 28 are highly hydrophobic (Fig. 1B) and predicted to
be a transmembrane domain by the TMPred software (http:
//www.ch.embnet.org/software/TMPRED_form.html). In or-
der to experimentally determine whether ORF7b is an integral
membrane protein, 293T cells were transfected with plasmids
expressing GFP fused to the N terminus of the cellular GTPase
Rab11 (GFP-Rab11, a protein that is found in the cytosol and
bound to membranes) (26), GFP fused to the N terminus of
SARS-CoV nucleocapsid protein (GFP-SARS N, a cytosolic
protein) (64), the influenza M2 protein (an integral membrane
protein) (31), or the ORF7b protein. At 18 h posttransfection,
cells were lysed in hypotonic lysis buffer, and the membrane
and cytosolic fractions were separated by high-speed centrifu-
gation. The resulting pellet (containing the cellular mem-
branes) was resuspended in PBS and treated with urea, alkaline
pH, or KCl—conditions known to extract peripheral membrane
proteins but not integral membrane proteins from membranes
(16, 52). The ORF7b protein pelleted with cellular membranes
after hypotonic lysis, as did the influenza A virus M2 protein
(Fig. 3). As expected, the cytosolic protein GFP-SARS N was
not present in the pellet, whereas the GFP-Rab11 was present
in both fractions, indicating that these centrifugation condi-
tions did not result in pelleting of a significant amount of
cytosolic proteins. Treatment of the pelleted membranes with
urea, carbonate, or KCl did not dissociate ORF7b or M2 from
membranes, indicating that both of these proteins were inte-
gral membrane proteins. The GFP-Rab11 protein was re-
moved from membranes with urea and carbonate, indicating
these conditions could strip peripheral membrane proteins
from membranes. KCl treatment did not dissociate GFP-
Rab11 from membranes, presumably because the interactions
that tether GFP-Rab11 to membranes are not ionic interac-
tions, and therefore are not disrupted by high amounts of KCl
(72). These results strongly suggest the ORF7b protein is an
integral membrane protein.
The ORF7b protein encodes cysteine residues at amino ac-
ids 12 and 41 (Fig. 1B). The cysteine at amino acid 41 is present
downstream of the predicted transmembrane domain, whereas
the cysteine at amino acid 12 lies within the predicted trans-
membrane domain. To determine whether the ORF7b protein
can form disulfide bond-linked oligomers, plasmids expressing
either the influenza A virus M2 protein or the SARS-CoV
ORF7b protein were transfected into 293T cells. At 18 h post-
transfection, the cells were lysed in 1% Triton X-100, polypep-
tides were separated by SDS-PAGE under either reducing or
nonreducing conditions, and the proteins were detected by
Western blotting. As shown in Fig. 4A, the M2 protein forms
characteristic dimers (d) and tetramers (t) under nonreducing
conditions (20) and exists as a monomer (m) under reducing
conditions. In contrast, no change in migration was detected
when the ORF7b protein was analyzed under reducing or
nonreducing conditions (Fig. 4B), indicating the protein does
not form disulfide-linked oligomers.
Subcellular localization of ORF7b. Since the SARS-CoV
ORF7b protein appears to be an integral membrane protein,
we investigated its subcellular localization after cDNA expres-
sion or in virus-infected cells by confocal microscopy of both
permeabilized and intact cells. As a positive control for surface
expression, cells were transfected with a plasmid containing the
cDNA for the influenza A virus M2 protein or a C-terminal
myc epitope-tagged M2 protein. M2 is a type III integral mem-
brane protein with an extracellular N terminus, an intracellular
C terminus and no signal peptide (31, 87). Cell surface expres-
sion of the M2 protein was discernible in permeabilized or
intact cells stained with the MAb 14C2 which recognizes the
extracellular N terminus of the protein (Fig. 5A, a to d). The
increased perinuclear staining observed in permeabilized cells
represents the M2 protein that accumulates in the Golgi com-
FIG. 3. The ORF7b protein is an integral membrane protein. 293T
cells were transfected with plasmids encoding the cDNAs for GFP-
Rab11, SARS-CoV GFP-N, M2 from influenza A virus, or SARS-CoV
ORF7b. At 18 h posttransfection, cells were collected, lysed in hypo-
tonic lysis buffer, and homogenized. The lysate was separated into
pellet (P) and supernatant (S) fractions by centrifugation at 100,000 
g. Pellets containing cellular membranes were subsequently treated
with 4 M urea, 50 mM Na2CO3 (pH 11.3), or 2 M KCl to disrupt
peripheral membrane proteins, and the samples were centrifuged at
100,000  g. The resultant pellet (P) and supernatant (S) were ana-
lyzed by Western blotting with rabbit anti-GFP polyclonal sera, anti-M2
MAb, or rabbit anti-ORF7b polyclonal sera.
FIG. 4. The ORF7b protein does not form disulfide-linked oli-
gomers. 293T cells were transfected with either control plasmid (mock)
or plasmids expressing the cDNAs for the influenza A virus M2 protein
(A) or SARS-CoV ORF7b (B). The cells were lysed 18 h posttrans-
fection, separated by SDS-PAGE under reducing (DTT) or nonre-
ducing (DTT) conditions, and analyzed for protein expression by
Western blotting. The M2 protein formed characteristic disulfide-
linked dimers (d) and tetramers (t) under nonreducing conditions and
monomers (m) in reducing conditions.
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partment as a result of intra-Golgi pH changes induced by the
protein (65). The C-terminal myc epitope-tagged M2 protein
was detected at the plasma membrane of permeabilized but
not intact cells (Fig. 5A, e to h), which is consistent with the
fact that the M2 C terminus is located in the cytoplasm and
therefore not accessible to antibody in nonpermeabilized cells
(87).
When cells transfected with the ORF7b cDNA were immu-
nostained with polyclonal antibodies raised to the entire
ORF7b protein, the protein was detected in a concentrated
perinuclear region with no significant staining associated with
the plasma membrane (Fig. 5A, m to p). ORF7b was detected
in permeabilized but not in intact cells. The expression pattern
of ORF7b was similar to that observed with SARS-CoV
ORF7a (Fig. 5A, i to l), which is not expressed at the plasma
membrane but localizes primarily to the Golgi compartment
(47).
Since the ORF7b epitopes that are recognized by the poly-
clonal ORF7b sera have not been mapped, it is not clear
whether antibodies to both the N and the C termini of the
protein are present in the polyclonal anti-ORF7b sera. Cells
transfected with a cDNA encoding ORF7b containing a C-
terminal myc epitope tag were immunostained to gain insight
into the membrane topology of the protein. Antibodies that
recognize the myc epitope-immunostained ORF7b in perme-
abilized but not in intact cells, indicating that the C terminus of
ORF7b was not exposed to the extracellular media. In addi-
tion, the lack of a discernible plasma membrane staining pat-
tern further supported the conclusion that ORF7b was most
likely retained at an intracellular site. In order to unambigu-
ously demonstrate that ORF7b targets to intracellular mem-
branes, 293T cells were transfected with plasmids expressing
the cDNAs of ORF7b and a short, acylated polypeptide fused
to GFP (S15-GFP), a protein previously demonstrated to bind
to the plasma membrane (60a). Cotransfected cells were ana-
lyzed by confocal microscopy (Fig. 5B, a to d). Little or no
colocalization (lack of yellow staining in the merge image)
between S15-GFP (green) and the ORF7b protein (red) was
detected, indicating that ORF7b is not present at the plasma
membrane of transfected cells.
The data in Fig. 5 indicate that the ORF7b protein does not
localize to the plasma membrane after expression from cDNA.
However, the data do not provide insights into the membrane
topology of the protein because an intracellularly targeted
protein will not have any epitopes exposed to the extracellular
milieu. The ORF7b protein could be a type III integral mem-
brane protein with its N terminus in the lumen and its C
terminus exposed to the cytoplasm, or it could be a type II
integral membrane protein with its N terminus exposed to the
cytoplasm and its C terminus in the luminal space. To distin-
guish between these possibilities, selective plasma membrane
permeabilization with digitonin was utilized. After transfection
with cDNAs encoding SARS-CoV ORF7a-GFP, C-terminal
myc-tagged M2 or C-terminal myc-tagged ORF7b, the cells
were either completely permeabilized with saponin or selec-
tively permeabilized with digitonin. To ensure the digitonin
treatment was selectively permeabilizing the plasma mem-
brane, ORF7a-GFP-expressing cells were immunostained with
an antibody, 2E11, which recognizes the luminal domain of the
protein (47). Whereas GFP staining was visible regardless of
permeabilization, the 2E11 immunostaining was only visible
after saponin permeabilization, indicating that the digitonin
was not permeabilizing the Golgi membranes (Fig. 6A, D, E,
and H). Immunostaining of cells expressing the C-terminally
tagged M2 protein showed antibody staining with both deter-
gent treatments, indicating the digitonin was in fact permeabi-
lizing the plasma membrane (Fig. 6B and F). Immunostaining
of the ORF7b-myc protein-expressing cells was detected under
both conditions, clearly indicating the C terminus of ORF7b-
FIG. 5. The ORF7b protein is not expressed on the cell surface of
transfected cells. (A) Vero cells were transfected with plasmids encod-
ing the cDNAs for the surface-expressed influenza A virus M2 protein
(a to d), a C-terminal myc-epitope tagged M2 protein (e to h), ORF7a
(i to l), ORF7b (m to p), or an ORF7b protein containing a C-terminal
myc epitope tag (q to t). Transfected cells were fixed and permeabil-
ized with 0.1% saponin (left columns) or stained with primary antibody
at 4°C and fixed immediately poststaining (nonpermeabilized). Cells
were incubated with antibodies specific for the indicated proteins, with
the exception of the myc epitope-tagged proteins, which were detected
with an anti-myc MAb. Only influenza virus M2 transfected cells
stained with the 14C2 MAb (targeting the N-terminal extracellular
domain of M2) demonstrated surface staining. (B) Vero cells were
cotransfected with cDNAs expressing ORF7b and a GFP construct
that localizes to the plasma membrane of transfected cells (S15-GFP).
At 18 h posttransfection, the cells were immunostained with antibodies
that recognize the ORF7b protein (red). The lack of colocalization
between the proteins further suggests little or no ORF7b is present at
the cell surface. All images were obtained with a 63 oil immersion
objective and represent a z-stack projection of 0.5-m slices obtained
by confocal microscopy. Nuclei were counterstained with TO-PRO-3
(blue).
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myc was exposed to the cytoplasm (Fig. 6C and G). Unfortu-
nately, introducing a myc epitope tag at the N terminus of
ORF7b altered the intracellular distribution of the protein,
preventing us from further characterizing the membrane ori-
entation of ORF7b (data not shown).
To determine the precise intracellular localization of
ORF7b, Vero cells transfected with a plasmid expressing the
cDNA for the ORF7b protein were analyzed by indirect im-
munofluorescence confocal microscopy. The ORF7b protein
exhibited a juxtanuclear localization pattern that highly colo-
calized with the cis-Golgi marker GM130 (Fig. 7A). The local-
ization of ORF7b was also analyzed in SARS-CoV-infected
Vero cells at 6 and 12 h postinfection (Fig. 7B). The ORF7b
protein colocalized with GM130 at both times postinfection,
indicating that the intracellular localization of ORF7b was
similar in cDNA-transfected and virus-infected cells. The
Golgi appears expanded and distended in SARS-CoV-infected
cells compared to those in mock-infected or cDNA-transfected
cells. This is most likely due to an expansion of the Golgi in
order to handle the large amount of viral glycoproteins tran-
siting through or localizing to the Golgi.
The subcellular localization of ORF7b was then compared
to those of a number of cellular proteins. For these studies, the
ORF7b-myc protein was used as rabbit and mouse antibodies
recognizing the myc epitope are available. The ORF7b-myc
protein colocalized with GM130 indicating the epitope-tagged
protein displayed the same intracellular localization as the
untagged protein (Fig. 7C). Interestingly, ORF7b-myc colocal-
ized with two other Golgi markers, the trans-Golgi network
marker Golgin-97 and the cis/medial-Golgi marker 	-manno-
sidase II (Fig. 7C), indicating that ORF7b-myc was present
throughout the Golgi stacks.
The ORF7b protein did not colocalize to a great extent with
the cellular proteins calnexin (ER resident protein), ERGIC53
(ER-to-Golgi intermediate compartment protein), or CD63
(lysosome/multivesicular body protein) (Fig. 7C). The amount
of colocalization of ORF7b-myc with CD63 (Fig. 7D), GM130
(Fig. 7E), or Golgin-97 (Fig. 7F) was quantified by reconstruct-
ing a three-dimensional image from the confocal images and
calculating a Pearson coefficient of colocalization (Fig. 7G)
(39). The ORF7b colocalization with GM130 (0.769
 0.068) and
Golgin-97 (0.645 
 0.040) was significantly higher than its
colocalization with CD63 (0.195 
 0.054), calnexin (0.252 

0.067), ERGIC53 (0.233 
 0.048), or the nuclear counterstain
TO-PRO-3 (0.074 
 0.106). The data from Fig. 7 clearly indi-
cate that the ORF7b protein localizes to the Golgi compart-
ment in SARS-CoV-infected cells and after expression from
cDNA.
ORF7b is incorporated into SARS-CoV virions. The as-
sembly and budding of coronavirus particles occurs at intra-
cellular membranes (reviewed in reference 4a). While the
precise intracellular location of SARS-CoV budding has yet
to be determined, several other coronaviruses bud into the
endoplasmic reticulum-Golgi intermediate compartment
(ERGIC) and the E and M proteins that drive the budding
process localize to the ERGIC or Golgi (11a, 11c, 36, 45).
Since ORF7b localized near the presumed site of SARS-
CoV budding, we investigated whether ORF7b was incor-
porated into virus particles.
Supernatant from SARS-CoV-infected cells was inactivated
with paraformaldehyde and then centrifuged over a 20% (wt/
vol) sucrose cushion in order to partially purify virus particles.
The pelleted virus particles were resuspended and analyzed by
SDS-PAGE and Western blotting for the expression of viral
and cellular proteins. SARS-CoV cell lysates contained the
expected viral (nsp8, S, and ORF7b) and cellular (-actin)
proteins, whereas mock-infected cells contained only -actin
(Fig. 8). The partially purified virus pellet contained the SARS-
CoV S and ORF7b proteins but did not possess a detectable
signal for the nsp8 protein or the cellular protein -actin (Fig.
8). The lack of -actin in the SARS-CoV virus pellet indicated
that there was not a significant amount of cellular contami-
nants in the preparation, and the lack of nsp8 protein indicated
that not all SARS-CoV proteins could be packaged into virus
particles.
The partially purified virus particle preparation was sub-
jected to ultracentrifugation on a continuous 20 to 60% su-
crose gradient for 18 h at 100,000  g. The sucrose gradients
were fractionated from the top, and each fraction was analyzed
by Western blotting for SARS-CoV N or ORF7b protein.
Fractions 8 to 10 contained the peak amounts of both SARS-
CoV N and ORF7b proteins, indicating the particles contain-
ing either protein cosedimented (Fig. 8B). The density of frac-
tions 8 to 10 was approximately 1.20 g/ml (Fig. 8C), which is
consistent with the density of SARS-CoV particles (23, 25).
Identical results were obtained with viruses inactivated with
FIG. 6. The C terminus of ORF7b is exposed to the cytoplasm.
Vero cells were transfected with plasmids expressing the cDNA for
ORF7a-GFP (A, D, E, and H), M2-myc (B and F), or ORF7b-myc (C
and G). At 18 h posttransfection, the cells were fixed with 2% para-
formaldehyde, washed extensively, and permeabilized with PBS con-
taining 0.1% saponin to disrupt all cellular membranes (A to D) or 25
g of digitonin/ml to selectively permeabilize the plasma membrane (E
to H). The cells were incubated with the 2E11 MAb, which recognizes
the luminal domain of ORF7a (A, D, E, and H), or the 9E10 MAb,
which recognizes the myc epitope tag (B, C, F, and G). The primary
antibodies were detected using a goat anti-mouse IgG conjugated to
Alexa Fluor 594 and mounted, and the cells were visualized by confo-
cal microscopy using a 63 oil immersion objective.
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-propiolactone (data not shown), suggesting the cosedimen-
tation of ORF7b and N was not dependent on the method of
virus inactivation. These data suggest the SARS-CoV ORF7b
protein is incorporated into virus particles.
It has recently been reported that the SARS-CoV 3a protein
is released from transiently transfected cells in membranous
structures (22). Coronavirus E proteins can also be released
from cDNA-transfected cells and are key components of the
virus budding machinery (10, 21, 22, 46). In order to determine
whether ORF7b could be secreted or associated with cellular
vesicles that are secreted, we analyzed the supernatants of cells
transfected with cDNA plasmids encoding ORF7b, influenza A
FIG. 7. The ORF7b protein localizes to the Golgi apparatus in cDNA transfected or SARS-CoV-infected cells. (A) Vero cells grown on
coverslips were transfected with a plasmid expressing the ORF7b cDNA. At 18 h posttransfection, the cells were immunostained with antibodies
against ORF7b (green) or the cis-Golgi marker protein GM130 (red) by using confocal microscopy. Nuclei were counterstained with TO-PRO-3
(blue). (B) Vero cells were plated onto coverslips and then infected at an MOI of 5.0 with SARS-CoV. At the indicated times postinfection, the
cells were fixed, and colocalization of ORF7b (green) with the cis-Golgi marker GM130 (red) was assessed by confocal microscopy. (C) Vero cells
grown on coverslips were transfected with a plasmid expressing the ORF7b protein containing a C-terminal myc-epitope tag and then assessed by
confocal microscopy for colocalization with cellular proteins that reside in various subcellular compartments (red) including the cis-Golgi network
(GM130), the trans-Golgi network (Golgin-97), cis- and medial-Golgi (	-mannosidase II), ER-to-Golgi intermediate compartment (ERGIC53),
ER (Calnexin), and lysosomes/multivesicular body (CD63). The ORF7b and ORF7b-myc antigen (green) colocalized with all three Golgi markers.
All images were obtained with a 63 oil immersion objective lens and represent a z-stack projection of 0.7-m slices obtained by confocal
microscopy. (D to F) Three-dimensional confocal images were generated by using Volocity software (Improvision) and analyzed for colocalization
between ORF7b (green) and GM130, Golgin-97, or CD63 (red). (G) Shown is a cross-section along the y axis of the cell. Nuclei were
counterstained with TO-PRO-3 (blue). The extent of colocalization was quantified for five cells in each condition, and the measure of fluorophore
colocalization is expressed as a Pearson correlation coefficient (39).
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virus M2 or WNV NS1. The influenza A virus M2 protein is an
integral membrane protein that is not secreted or shed from
transfected cells, while the WNV NS1 protein is secreted from
infected or transfected cells in a glycosylated form (37). West-
ern blotting of transfected cell lysates indicated that all of the
proteins were expressed (Fig. 9). When transfected cell super-
natants were analyzed, no ORF7b was detected, indicating the
ORF7b protein is not secreted into the media of cDNA-trans-
fected cells (Fig. 9). As expected, no influenza A virus M2
protein was present in the supernatants, whereas the WNV
NS1 protein was readily detected.
To confirm the association of ORF7b with virus particles,
FIG. 8. The ORF7b protein is present in purified virus particles. (A) SARS-CoV particles were inactivated with paraformaldehyde, the
supernatant was precleared by centrifugation at 1,000  g and layered on a 20% sucrose cushion, and virus particles were pelleted at 100,000 
g. The virus pellet was resuspended in 2 Laemmli SDS-PAGE buffer, and protein expression was detected by Western blotting. The virus lysate
contains no -actin or nsp8 but is enriched for both S (the asterisk indicating a highly glycosylated virus associated form of S) and ORF7b. (B) The
inactivated, pelleted virus particles were loaded onto a 20 to 60% continuous sucrose gradient and centrifuged for 18 h at 100,00  g, and 1-ml
fractions were collected from the top. The fractions were analyzed for the presence of SARS-CoV N or ORF7b by Western blotting. (C) The
density of each fraction of the 20 to 60% sucrose gradient was determined by weighing 100 l of the fraction.
FIG. 9. The ORF7b protein is not secreted from transfected cells. 293T cells were transfected with plasmids encoding the cDNAs for the
influenza A virus M2 protein, the WNV NS1 protein, or the SARS-CoV ORF7b protein. Mock samples were transfected with the plasmid vector
containing no cDNA insert. At 18 h posttransfection, supernatants were collected and centrifuged at 1,000  g to remove cellular debris, and an
equal volume of 2 Laemmli SDS-PAGE buffer was added. Samples were analyzed by Western blotting for the indicated proteins. NS1 was present
in cell lysates (l) and secreted (s) as a higher-molecular-weight glycosylated form, whereas the M2 and ORF7b proteins were present only in the
cell lysates.
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infected Vero cells were analyzed by immunogold labeling and
electron microscopy (Fig. 10). At 12 (Fig. 10A) and 24 h (data
not shown) postinfection, intracellular SARS-CoV particles
were labeled strongly with anti-ORF7b antibodies. The asso-
ciation of ORF7b with SARS-CoV virions was further con-
firmed by dual-labeling experiments with anti-ORF7b (arrows)
and anti-N (arrowheads) antibodies (Fig. 10B). Both antibod-
ies labeled intracellular virions. A more direct association of
the ORF7b protein with the SARS-CoV is shown in Fig. 10C,
where purified SARS-CoV particles were decorated with anti-
ORF7b antibodies, further indicating the ORF7b protein is
packaged into SARS-CoV particles.
DISCUSSION
Coronavirus accessory genes have been shown to play im-
portant roles in the in vivo replication and pathogenesis of a
number of coronaviruses (11b, 49). However, there are a num-
ber of coronavirus accessory genes whose function has yet to be
determined (4, 44, 85b). In this report, the expression of the
SARS-CoV ORF7b protein was confirmed in SARS-CoV-in-
fected cells and after expression of the gene 7 coding region
from a eukaryotic expression plasmid. To date, the expression
of the SARS-CoV ORF3a (14a, 22, 25, 68, 86) and ORF7a (47,
87a) accessory proteins has been demonstrated in infected
cells, but both of those proteins are located near the 5 end of
their respective sgRNAs and are therefore in a favorable po-
sition for translation. Expression of the ORF3b, ORF6,
ORF8a, ORF8b, and ORF9b proteins in SARS-CoV-infected
cells has yet to be demonstrated, although sera from SARS-
CoV-infected patients does contain antibodies to some of
these proteins (16b). To our knowledge, the present study
represents the first documentation of a SARS-CoV bicistronic
RNA encoding an accessory protein. However, bicistronic
RNAs have been identified in other coronaviruses, including
all coronavirus replicase ORF1a/1b genes (1, 1a, 12), the bo-
vine coronavirus N and I proteins (66, 67), the MHV ORF5a
and ORF5b (80b), the IBV 5a and 5b proteins (4), the IBV 3a
and 3b proteins (18), the TGEV 3a and 3b proteins (48a), and
the TGEV 7a and 7b proteins (49). Although we cannot for-
mally rule out the presence of a sgRNA whose transcript ini-
tiates at a noncanonical sequence allowing for monocistronic
expression of ORF7b, it is clear from our studies of gene 7
expression from cDNA that the ORF7b protein can be trans-
lated in the context of a sgRNA 7-like transcript.
The biochemical and cell biological data suggest that the
ORF7b protein is an integral membrane protein that localizes
to the Golgi apparatus and has its C terminus exposed to the
cytoplasm. The ORF7b protein is most likely a type III integral
membrane protein; however, we were not able to raise anti-
bodies to the N terminus of the protein, nor were we able to
successfully epitope tag the N terminus of the protein without
altering the intracellular localization of the protein. Introduc-
tion of potential N-linked glycosylation sites into the N termi-
nus of the protein did not lead to the production of a glyco-
sylated form of ORF7b, although the limited number of amino
acids in the predicted luminal domain of ORF7b (nine amino
acids) may preclude access to the glycosylation machinery
(data not shown). It is interesting that the M2 protein of
influenza A virus—a type III integral membrane protein—has
a membrane-proximal sequence for N-linked glycosylation in
its luminal domain that is not recognized by cellular glycosyl-
ation enzymes (87). For these reasons, formal proof of the
ORF7b orientation in membranes must await the development
of additional reagents.
The ORF7b protein was found to be a structural component
of SARS-CoV virions, making it the third accessory gene to be
FIG. 10. Immunogold staining for ORF7b in SARS-CoV particles.
Cryosections from SARS-CoV-infected Vero cells were immunola-
beled with antibodies raised against ORF7b (A and B) or the SARS-
CoV N protein (B) and visualized with 10-nm or 5-nm protein A-gold,
respectively. Localization of the ORF7b protein to intracellular virions
is highlighted with arrows in panels A and B, and colocalization with N
protein (arrowheads) is shown in panel B. (C) Immunolabeling of
ORF7b on purified SARS-CoV particles. Magnification bars represent
200 nm in panels A and B and 100 nm in panel C.
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found in virions. The importance of virion incorporation to
ORF7b protein function will be an important question to ad-
dress in future studies. Both the ORF3a (25, 68) and the
ORF7a (21) accessory proteins have been determined to be
SARS-CoV structural proteins. This is not surprising, since all
three of these proteins localize to the Golgi compartment and
are therefore quite close to the presumed site of SARS-CoV
budding. The incorporation of viral proteins into SARS-CoV
particles is not well understood, and it will be important to
determine whether specific virion incorporation signals are
present in ORF7b or whether it is simply packaged into the
SARS-CoV particles because it is present in high amounts near
the virus budding site. The latter would be similar to the
pseudotyping of retroviral cores with integral membrane pro-
teins expressed at high levels (11).
As yet, no function has been ascribed to the ORF7b protein
and a recombinant SARS-CoV encoding GFP in place of the
gene 7 coding region is not attenuated in mice or in primary
human airway epithelial cell cultures (69, 85b). Furthermore, a
mouse hepatitis virus (strain JHM) encoding ORF7b as an
extra gene displayed no change in virulence or replication
compared to the parental virus (53). Since the mouse is a good
model for in vivo replication of SARS-CoV but not for SARS-
CoV pathogenesis, it is possible that the protein may be dis-
pensable for replication in mice but not in other SARS-CoV
animal models of infection such as hamsters (60), bats (32, 55),
civit cats (84), ferrets (41, 80), cats (41), or nonhuman primates
(34, 41a, 57, 63a, 82). Alternatively, the ORF7b protein may be
essential for virus replication in the as-yet-unidentified natural
host of the virus. Our studies of the translation of ORF7a and
ORF7b provide insight into how to make recombinant SARS-
CoVs that expresses only one of the two gene 7 products
without altering the level of expression of the other gene prod-
uct. This is an important concept, since it will allow one to
attribute a replication phenotype to the absence of one gene
product and not the over- or underexpression of the other.
The high degree of conservation between the SARS-CoV
and bat coronavirus gene 7 sequences implies the gene 7 prod-
ucts are conserved or selected for in a natural infection. Elu-
cidating a role for the gene 7 products in SARS-CoV infection
will require a careful, methodical analysis of SARS-CoV rep-
lication, pathogenesis, and host immune response in an appro-
priate animal model. However, valuable insights into the cell
biology of SARS-CoV gene expression can be gained through
the study of the translation and cell biology of SARS-CoV
accessory gene proteins.
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